Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2018-03-19EMA Refused: Fanaptum (iloperidone) — Vanda Pharmaceuticals Ltd
The EMA refused the marketing authorization for Fanaptum (iloperidone) from Vanda Pharmaceuticals Ltd for schizophrenia.
-
CLINICAL_TRIALS withdrawal · 2018-03-13Clinical Trial Update: Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia [NA]
A clinical trial evaluating transcranial direct current stimulation for hallucinations in first-episode schizophrenia has been withdrawn fro…
-
CLINICAL_TRIALS withdrawal · 2017-11-29Clinical Trial Update: Safety and Tolerability of Varenicline in Schizophrenia (SATOVA) [Phase 4]
A Phase 4 trial evaluating the safety and tolerability of varenicline in schizophrenia and schizoaffective disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
A clinical trial studying nicotinic receptor density in smokers and non-smokers with schizophrenia was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-30Clinical Trial Update: Nicotinic Receptors and Schizophrenia [Phase 1, Phase 2]
A Phase 1/2 clinical trial investigating nicotinic receptor targets for schizophrenia has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2016-10-13Clinical Trial Update: Antipsychotic Discontinuation in High-risk Subjects
A clinical trial evaluating antipsychotic discontinuation in high-risk individuals with schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-15Clinical Trial Update: Sodium Butyrate For Improving Cognitive Function In Schizophrenia [Phase 2, Phase 3]
Phase 2/Phase 3 trial of sodium butyrate for improving cognitive function in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-01Clinical Trial Update: Comparison of the Effectiveness of Brexpiprazole With That of Risperidone [Phase 3]
Phase 3 trial comparing brexpiprazole with risperidone for schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients [NA]
The trial evaluating non-invasive brain stimulation for medication-resistant auditory hallucinations in schizophrenia has been withdrawn.
-
EMA withdrawal · 2016-03-29EMA Application withdrawn: Aripiprazole Mylan (aripiprazole) — Mylan S.A.S.
The EMA withdrew the application for Aripiprazole Mylan (aripiprazole) by Mylan S.A.S. for schizophrenia.
-
CLINICAL_TRIALS withdrawal · 2016-02-09Clinical Trial Update: Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia [Phase 2]
Phase 2 clinical trial of Org 24448 (an ampakine) for cognitive deficits in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-05Clinical Trial Update: NRX-1074 in Early Course Schizophrenia [Phase 2]
A Phase 2 trial of NRX-1074 for early course schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-12-17Clinical Trial Update: Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) [Phase 2]
A Phase 2 trial evaluating SCH 900435 for schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-12-09Clinical Trial Update: Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients [NA]
A clinical trial comparing clozapine with amisulpride in treatment-resistant schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-10-12Clinical Trial Update: Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia [Phase 2]
A Phase 2 trial evaluating targeted Vitamin D treatment for schizophrenia-associated hyperprolinemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-04Clinical Trial Update: A Survey of Sexual Function in Schizophrenic Patients
This clinical trial update notes that a study assessing sexual function in schizophrenia patients was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-03Clinical Trial Update: Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia [Phase 1]
A Phase 1 clinical trial evaluating deep brain stimulation for treatment-refractory negative symptoms in schizophrenia has been withdrawn.
-
EMA withdrawal · 2015-07-20EMA Application withdrawn: Aripiprazole Mylan (aripiprazole) — Generics (UK) Limited
The EMA report indicates withdrawal of the aripiprazole generic application from Generics (UK) Limited for schizophrenia and bipolar disorde…
-
CLINICAL_TRIALS withdrawal · 2015-05-07Clinical Trial Update: Usability of a Website for People With Schizophrenia [NA]
The NIMH-sponsored clinical trial evaluating a website usability for people with schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder [Phase 2]
Phase 2 study evaluating the Medical Information Device #1 (MIND1) for adherence, safety, and tolerability in schizophrenia or Bipolar I dis…
-
CLINICAL_TRIALS withdrawal · 2014-07-31Clinical Trial Update: Cardio Risk of Acute Schizophrenia Olanzapine Duke [Phase 4]
A Phase 4 clinical trial evaluating cardiac risk with olanzapine in acute schizophrenia/schizoaffective disorder was withdrawn.
-
EMA withdrawal · 2014-07-24EMA Withdrawn: Olanzapine Cipla (previously Olanzapine Neopharma) (olanzapine) — Cipla (EU) Limited
EMA withdrew Olanzapine Cipla (formerly Olanzapine Neopharma) in the EU; therapeutic areas include schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS withdrawal · 2014-06-12Clinical Trial Update: Glycine and D-Cycloserine in Schizophrenia [Phase 3]
Phase 3 trial evaluating glycine and D-cycloserine for schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-06-04Clinical Trial Update: Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia [Phase 2]
Phase 2 trial of sarcosine as preventive therapy for individuals at high risk for schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-12-23Clinical Trial Update: Zyprexa and Task Engagement in Schizophrenia [Phase 3]
A Phase 3 trial evaluating Zyprexa (olanzapine) for task engagement in schizophrenia has been withdrawn.